Biomea Fusion to Participate in Citi's SMID Biotech C-Suite Fireside Chat Series
Biomea Fusion (Nasdaq: BMEA) will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025 at 8:00 a.m. PT / 11:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Biomea Fusion (Nasdaq: BMEA) will participate in Citi's SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025 at 8:00 a.m. PT / 11:00 a.m. ET. A live audio webcast will be available via the company's Investors & Media site and a replay will be posted after the event. The company is a clinical-stage diabetes and obesity firm and will join the session as scheduled.
Investors can access the live audio webcast and subsequent replay at https://investors.biomeafusion.com/news-events/events.
Details
News Market Reaction – BMEA
On Oct 22, the first trading day after this news, BMEA closed 9.43% below the previous close.
Data tracked by StockTitan Argus for the Oct 22 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in Citi’s SMID Biotech C-Suite Fireside Chat Series on Thursday, October 23, 2025, at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.
A live audio webcast of the discussion will be available here or by visiting the Investors & Media section of Biomea’s website at https://investors.biomeafusion.com/news-events/events. A replay of the webcast will be available following the live event.
About Biomea Fusion
Biomea Fusion is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecule therapies, icovamenib and BMF-650, for diabetes and obesity. These programs target metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director of Investor Relations and Corporate Development
ir@biomeafusion.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.